Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.47 |
| ▸ | BACE1 | P56817 | 7/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391905 | 0.94 | ACHE (0.49) | ACHEBACE1BCHENPC1RAB9A | |
| SCHEMBL930250 | 0.79 | ACHE (0.45) | ACHEBACE1BCHENPC1RAB9A | |
| SCHEMBL930233 | 0.73 | CHRNA7 (0.52) | ACHEBACE1BCHENPC1RAB9A | |
| SCHEMBL2124990 | 0.72 | ACHE (0.49) | ACHEBACE1BCHENPC1RAB9A | |
| SCHEMBL2676639 | 0.71 | CHRNA7 (0.64) | HTR3A | |
| Trifluoroacetic Acid SCHEMBL1793487 | 0.71 | HDAC3 (0.39) | ACHEBACE1BCHENPC1RAB9A | |
| SCHEMBL928882 | 0.71 | ACHE (0.45) | ACHEBACE1BCHENPC1RAB9A | |
| SCHEMBL3134466 | 0.71 | MBTD1 (0.46) | HTR3A | |
| SCHEMBL2676610 | 0.70 | CHRNA7 (0.51) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL2678100 | 0.70 | HRH3 (0.57) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173658-B2 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S (DK) | 2012-05-08 | — | — | US | claimed |
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S | 2008-11-13 | — | — | US | claimed |
| US-8173658-B2 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| EP-2246352-A1 | Novel diazabicyclic aryl derivatives and their medical use | NeuroSearch AS (DK) | 2010-11-03 | — | — | EP | disclosed |
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | ACHE, CHRNA6, CHRNA10 | ACHE 1/4885BACE1 317/4885BCHE 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.